Vivos Therapeutics (VVOS) Q2 FY26 earnings call

Vivos Therapeutics reported significant revenue growth in Q2 FY26, driven by its strategic pivot towards sleep centers and service-based offerings, particularly through the Sleep Center of Nevada (SCN) acquisition. The company is actively pursuing multiple initiatives, including remote patient monitoring and DME-based CPAP programs, to establish recurring revenue streams and achieve cash flow positivity by late 2026 or early 2027. Despite operational progress and an expanding gross margin, the company faces substantial financial headwinds, including a going concern warning and NASDAQ non-compl